Massachusetts General Hospital reports safety and sustained immune responses in a Phase I trial of its individualized mRNA neoantigen therapy, INT (mRNA-4157/V940), which holds FDA breakthrough designation.medicalxpress.com
Concurrently, a new review outlines how multivalent mRNA-exosome vaccines and advanced lipid nanoparticles may overcome resistance in immunologically cold tumors by optimizing transcript architecture and delivery vectors.PubMed
Nothing published in the last 14 days cleared the bar. Below is the most relevant background we're tracking.
Relevant work from earlier we're still surfacing — not today's news.